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’INTRODUCTION
In a previous study, we established that 11(R)-HETE was a
signiﬁcant COX-2-derived AA metabolite in epithelial cells.
1
However, the consequences of this ﬁnding were not clear at that
time. A number of toxic substances including arsenite,
2 dioxin,
3
benzo[a]pyrene diol epoxide,
4 and cigarette smoke
5 upregulate
COX-2 expression, which in turn regulates numerous intracel-
lular biochemical pathways. This occurs primarily through the
biosynthesis of COX-2-derived AA metabolites, which can
exert cell-speciﬁce ﬀects on inﬂammation, cell growth, and
proliferation. For example COX-2-derived prostaglandin (PG)
E2 increases tumor proliferation through multiple mechanisms
including activation of plasma membrane G-protein-coupled
receptors and the nuclear peroxisome proliferator-activated
receptor (PPAR)γ.
6
Steady-state levels of PGE2 are maintained by PGE-
synthase-mediated biosynthesis from COX-2-derived PGH2
and catabolism by 15-PGDH-mediated inactivation to 15-oxo-
PGE2 (Figure 1).
7,8 The 15-oxo-PGE2 is then converted
to 13,14-dihydro-15-oxo-PGE2 by 15-oxoprostaglandin-Δ
13
reductase.
9 Loss of 15-PGDH expression is associated with
tumor formation in bladder, breast, colon, intestine, kidney,
lung, pancreas, stomach, and skin cancer.
7,8,10 14 Thus, upregu-
lation of COX-2
6 and downregulation of 15-PGDH
10 provides a
switch toward endogenous mediators that are signiﬁcant con-
tributors to cancer progression.
15
PGD2, another COX-2-derived metabolite, is also metabo-
lized by 15-PGDH to form 15-oxo-PGD2, which is then con-
verted to the corresponding inactive 13,14-dihydro derivative
(Figure 1).
16 Alternatively, PGD2 undergoes albumin-mediated
dehydration to give PGJ2, followed by a further dehydration to
give 15-deoxy-Δ
12,14-prostaglandin J2 (15d-PGJ2) (Figure 2).
17
Previousstudieshaveshownthat15d-PGJ2isaPPARγagonist,
18
which inhibits HUVEC proliferation in culture.
19 In addition, 15d-
PGJ2 can induce caspase-mediated endothelial cell apoptosis
20 and
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ABSTRACT: Previously, we established that 11(R)-hydroxy-
5,8,12,14-(Z,Z,E,Z)-eicosatetraenoic acid (HETE) was a sig-
niﬁcantcyclooxygenase(COX)-2-derivedarachidonicacid(AA)
metabolite in epithelial cells. Stable isotope dilution chiral liquid
chromatography (LC)-electron capture atmospheric pressure
chemical ionization (ECAPCI)/mass spectrometry (MS) was
used to quantify COX-2-derived eicosanoids in the human
colorectal adenocarcinoma (LoVo) epithelial cell line, which
expresses both COX-2 and 15-hydroxyprostaglandin dehydro-
genase (15-PGDH). 11(R)-HETE secretion reached peak
concentrations within minutes after AA addition before rapidly diminishing, suggesting further metabolism had occurred.
Surprisingly, recombinant 15-PGDH, which is normally speciﬁc for oxidation of eicosanoid 15(S)-hydroxyl groups, was found
to convert 11(R)-HETE to 11-oxo-5,8,12,14-(Z,Z,E,Z)-eicosatetraenoic acid (ETE). Furthermore, LoVo cell lysates converted
11(R)-HETE to 11-oxo-ETE and inhibition of 15-PGDH with 5-[[4-(ethoxycarbonyl)phenyl]azo]-2-hydroxy-benzeneacetic acid
(CAY10397) (50 μM) signiﬁcantly suppressed endogenous 11-oxo-ETE production with a corresponding increase in 11(R)-
HETE.ThesedataconﬁrmedCOX-2and15-PGDHasenzymesresponsiblefor11-oxo-ETEbiosynthesis.Finally,additionofAAto
the LoVo cells resulted in rapid secretion of 11-oxo-ETE into the media, reaching peak levels within 20 min of starting the
incubation. This was followed by a sharp decrease in 11-oxo-ETE levels. Glutathione (GSH) S-transferase (GST) was found to
metabolize 11-oxo-ETE to the 11-oxo-ETE-GSH (OEG)-adduct in LoVo cells, as conﬁrmed by LC MS/MS analysis.
Bromodeoxyuridine (BrdU)-based cell proliferation assays in human umbilical vein endothelial cells (HUVECs) revealed that
the half-maximal inhibitory concentration (IC50) of 11-oxo-ETE for inhibition of HUVEC proliferation was 2.1 μM. These results
show that11-oxo-ETEisanovelCOX-2/15-PGDH-derivedeicosanoid,whichinhibitsendothelialcellproliferationwithapotency
that is similar to that observed for 15d-PGJ2.2228 dx.doi.org/10.1021/tx200336f |Chem. Res. Toxicol. 2011, 24, 2227–2236
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inhibit the nuclear factor kB( N F kB) pathway.
21,22 It can also
increase levels of p53 in HUVECs, activate p53 phosphorylation,
and induce p21.
23
Studies of puriﬁed COX enzymes have shown that 11(R)-
HETE,15(S)-hydroxy-5,8,11,13-(Z,Z,Z,E)-eicosatetraenoicacid
(15(S)-HETE), and 15(R)-HETE are the major HETEs that are
formed.
24TheHETEsarisefromreductionofthecorresponding
hydroperoxyeicosatetraenoicacids(HPETEs)primarilythrough
the peroxidase (POX) activity of COXs (Figure 1).
25 11(R)-
HETE was a signiﬁcant eicosanoid secreted by AA-treated rat
intestinal epithelial cells that stably express COX-2 (RIES cells),
but it was rapidly metabolized.
1 15(S)-HETE was formed in
lower abundance and metabolized to 15-oxo-ETE,
24,26 as ex-
pected from its 15(S)-conﬁguration and the substrate speciﬁcity
of 15-PGDH. 15-Oxo-ETE was also found to inhibit endothelial
cell proliferation, although at concentrations higher than 15d-
PGJ2.
26 However, there is little evidence that 15d-PGJ2 can be
formed in vivo at concentrations commensurate with an endo-
genous antiproliferative role.
27 In our earlier study,
1 the meta-
bolic fate of 11(R)-HETE secreted by the RIES cells was not
established. 11-Oxo-ETE has now been synthesized, and a LC-
selected reaction monitoring (SRM)/MS method for its analysis
has been developed. This has made it possible to determine
whether 11-oxo-ETE is secreted by human epithelial cell lines
with upregulated COX-2 expression and to identify the dehy-
drogenase responsible. The ability of 11-oxo-ETE to modulate
HUVEC proliferation has also been examined.
’EXPERIMENTAL PROCEDURES
Chemicals and Reagents. AA (peroxide-free), 11(R,S)-HETE,
15(R,S)-HETE, [
2H8]-15(S)-HETE, [
13C20]-15-oxo-ETE, 15-oxo-ETE,
PGE2,[
2H4]-PGE2, 13,14-dihydro-15-keto-PGE2,[
2H4]-13,14-dihydro-
15-keto-PGE2,15d-PGJ2,CAY10397,proteaseinhibitorcocktailandrecom-
binant human 15-PGDH were purchased from Cayman (Ann Arbor, MI).
The Dess Martin reagent [1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benzio-
doxol-3-(1H)-one], 2,3,4,5,6-pentafluorobenzyl (PFB) bromide, Trizma-
HCl, lipoxidase from Glycine max (soybean), sodium borohydride, and
NAD
+werepurchasedfromSigma-Aldrich(St.Louis,MO).Fetalbovine
serum (FBS) was from Gemini Bioproducts (West Sacramento, CA).
F12K medium, DMEM medium, Medium 200 (M200), D-glucose, L-
glutamine, low-serum growth supplement (LSGS) kit, penicillin, and
streptomycinweresuppliedbyInvitrogen(Carlsbad,CA).LC MSgrade
water, hexane, methanol, isopropanol, acetonitrile and dichloromethane
were obtained from Fisher Scientific (Pittsburgh, PA). Gases were
supplied by The Linde Group (Munich, Germany). [
13C20]-AA was
obtained from Spectra Stable Isotopes (Columbia, MD).
Cell Culture. Human colorectal adenocarcinoma LoVo cells (ATCC,
Manassas, VA) were cultured in F12K medium supplemented with
Figure 1. Formation and action of COX-2-derived eicosanoids in epithelial cell models. AA is released from membrane phospholipids by calcium-
dependent cytosolic phospholipase A2 (cPLA2). The released AA undergoes COX-2-mediated metabolism to PGs or forms the lipid hydroperoxides,
15(S)-hydroperoxyeicosatetraenoic acid (HPETE), 15(R)-HPETE and 11(R)-HPETE, which are reduced to the corresponding HETEs. PGD2 and
PGE2 are inactivated by 15-PGDH-mediated conversion to their 15-oxo metabolites. Both 15-oxo-PGD2 and 15-oxo-PGE2 are converted to 13,14-
dihydro-5-oxo-PG metabolites. Intact PGD2 secreted by the epithelial cells can undergo albumin-mediated dehydration to 15d-PGJ2. PGE2 secreted
from the epithelial cells by the ABCC4 transporter is proproliferative for tumor cells. Reuptake of PGE2 by OATP2A1 into the epithelial cells leads to
further15-PGDH-mediatedinactivation.IncontrasttoPGE2andPGD2,15(S)-HETEand11(R)-HETEareactivatedby15-PGDH-mediatedoxidation
to 15-oxo-ETE and 11-oxo-ETE, respectively. The oxo-ETEs are further conjugated to form OEGs. Secreted 15- and 11-oxo-ETE that escape further
metabolism can then inhibit endothelial cell proliferation. Therefore, downregulation of 15-PGDH and OATP2A1 would result in increased PGE2-
mediated tumor and endothelial cell proliferation.2229 dx.doi.org/10.1021/tx200336f |Chem. Res. Toxicol. 2011, 24, 2227–2236
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10% FBS, 2 mM L-glutamine, 100,000 units/L penicillin and 100 mg/L
streptomycin. Human colonic adenocarcinoma HCA-7 Colony 29 cells
(Sigma-Aldrich, St. Louis, MO) weregrownin DMEM supplemented with
10% FBS, 2 mM L-glutamine, 110 mg/L sodium pyruvate, 100,000 units/L
penicillin and 100 mg/L streptomycin. For lipidomics analysis, the culture
m e d i u mw a sr e p l a c e dw i t hs e r u m - f r e eF 1 2 Ko rD M E Mm e d i u mb e f o r e
the treatment. HUVECs were obtained from Invitrogen (Carlsbad, CA)
a n dc u l t u r e do nc o l l a g e nI - c o a t e dt issue culture dishes in Medium 200
supplemented with LSGS kit. Cell proliferation assays were performed
using HUVECs from passage 4.
Mass Spectrometry. A triple stage quadrupole (TSQ Quantum)
mass spectrometer (Thermo Electron, San Jose, CA) equipped with an
APCIsourcewas usedforthequantitative lipidomics analyses. Targeted
chiral LC-ECAPCI/SRM/MS analysis was conducted using PFB deri-
vatives of 7 lipids and 4 heavy isotope analogue internal standards. For
the lipidomics profile, the instrument was operated in the negative ion
mode, and unit resolution was maintained for both precursor and
fragment ions. Operating conditions for the TSQ Quantum were as
follows: vaporizer temperature at 450 C; heated capillary temperature
at 250 C with the corona discharge needle set at 30 μA; nitrogen as
sheath (25 psi) and auxiliary (5 arbitrary units) gas. Collision-induced
dissociation (CID) was performed using argon as the collision gas at
2.7 mTorr in the rf-only quadrupole. The following SRM transitions
wereused:11-oxo-ETE-PFB,m/z317f165(collisionenergy(CE),25eV);
15-oxo-ETE-PFB, m/z 317 f 113 (CE, 18 eV); [
13C20]-15-oxo-ETE-
PFB, m/z 337 f 120 (CE, 18 eV); 11(R)-HETE-PFB, m/z 319 f 167
(CE, 16 eV); [
2H8]-15(S)-HETE-PFB, m/z 327 f 226 (CE, 13 eV);
PGE2-PFB,m/z351f271(CE,18eV);[
2H4]-PGE2-PFB,m/z355f
275 (CE, 18 eV); 13,14-dihydro-15-keto-PGE2-PFB, m/z 351 f 235
(CE, 22 eV); [
2H4]-13,14-dihydro-15-keto-PGE2-PFB, m/z 355 f 239
(CE, 22 eV).
ForGSHadductanalysis,themassspectrometerwasoperatedinthe
positive ion mode with an electrospray ionization (ESI) source. The
operating conditions were as follows: spray voltage at 4 kV; capillary
temperature at 350 C; nitrogen as sheath (35 psi) and auxiliary
(13 arbitrary units) gas. CID was performed using argon as the collision
gasat2.7mTorrintherf-onlyquadrupole.ThefollowingSRM transition
(m/z 626 f 497) was monitored for 11-oxo-ETE-GSH (CE, 18 eV).
LiquidChromatography.LCseparationswereconductedusinga
WatersAlliance2690HPLCsystem.AChiralpakAD-Hcolumn(250 
4.6 mm inner diameter, 5 μm; Daicel) was employed for normal phase
separation (flow rate 1 mL/min) of PFB derivatives of eicosanoids.
Gradient1wasusedforseparatingPFB-derivativesofHETEsandPGE2,
whereas gradient 2 was used for PFB derivatives of oxo-ETEs. For
gradient 1, solvent A was hexane, and solvent B was methanol/
isopropanol (1:1; v/v). Gradient 1 was as follows: 2% B at 0 min, 2%
B at 3 min, 3.6% B at 11 min, 8% B at 15 min, 8% B at 27 min, 50% B at
30min,50%at35min,and2%Bat37min.Separationswereperformed
at 30 C using a linear gradient. For gradient 2, solvent A was hexane,
and solvent B was isopropanol/hexane (6:4; v/v). Gradient 2 was as
follows: 2% B at 0 min, 2% B at 14.5 min, 12% B at 15 min, 23% B at
19 min, 90% B at 19.5 min, 90% B at 23.5 min, and 2% B at 24 min.
A Chiralpak AD-RH column (150   4.6 mm inner diameter,
5 μm; Daicel)was used for reversed phase (isocratic method 1, ﬂow
rate 0.5 mL/min) separation of the underivatized 11-oxo-ETE. The
mobile phase for isocratic separations was methanol/water/formic
acid (95:5:0.1; v/v).
Chemically synthesized 11-oxo-ETE was puriﬁed by normal-phase
(isocratic method 2) preparative LC (Ultrasphere 250   10 mm, inner
diameter,5μm;Beckman)usingWatersAlliance2690HPLCsystemby
monitoring the UV absorbance at 236 nm. The mobile phase for the
isocratic method 2 (ﬂow rate 2.5 mL/min) was hexane/isopropanol/
acetic acid (98.5:1.5:0.1 ; v/v).
GSH adducts were separated by reversed phase using gradient 3
on Waters Alliance 2690 HPLC system. The separation employed a
Phenomenex Synergi Hydro-RP column (150   4.6 mm inner dia-
meters, 5 μm). Solvent A was 0.1% aqueous formic acid, and solvent B
wasmethanol/acetonitrile(50:50;v/v).Gradient3wasasfollows:2%B
at 0 min, 2% B at 14 min, 30% B at 20 min, 42% B at 21 min, 65% B at
27 min, 80% B at 29 min, 90% B at 33 min, 90% B at 34 min, 2% B at
35min.Theﬂowratewas0.4mL/min.Theseparationwasperformedat
ambient temperature using a linear gradient.
PFB Derivatization. Eicosanoids were dissolved in 100 μLo f
acetonitrile and then reacted with 100 μLof PFBbromidein acetonitrile
(1:19;v/v)and100μLofdiisopropylethylamineinacetonitrile(1:9;v/v)
at room temperature for 30 min. The derivatives were evaporated to
dryness,dissolvedin100μLofhexane/ethanol(95:5;v/v)andanalyzed
by chiral LC-ECAPCI/SRM/MS.
Enzymatic Conversion of 11(R)-HETE by 15-PGDH. Various
concentrations of 11(R)-HETE (0, 2.3 μM, 4.6 μM, 6.9 μM, 9.2 μM
and 23 μM) were incubated with 9 nM recombinant human 15-PGDH
(52.2 ng, 1.8 pmol) and cofactor NAD
+ (400 μM) in 50 mM Tris-Cl
(pH7.9)for3.5minat37C.Eachtotalreactionvolumewas200μL.After
a3.5minincubation,theenzymaticreactionwasquenchedwith400μLof
ice cold methanol and [
13C20]-15-oxo-ETE (8 ng) added as the internal
standard. Eicosanoids were extracted with 1.2 mL of dichloromethane/
methanol (8:1; v/v). The lower organic layer was then evaporated to
dryness under nitrogen and reconstituted in methanol (100 μL). An
aliquot (25 μL) was separated using the isocratic method 1 and analyzed
by LC ESI/MS as described above. The retention time for 11-oxo-ETE
was 8.7 min. In separate experiments, the formation of 11-oxo-ETE was
found to be linear for the first 5 min. Eicosanoids were quantified by
interpolation from a standard curve prepared with 11-oxo-ETE using
[
13C20]-15-oxo-ETE as the internal standard.
Chemical Synthesis and Purification of 11-Oxo-ETE. The
Dess Martin reagent (2 mg, 4.7 μmol) was added to a solution of
11(R,S)-HETE (0.5 mg, 1.6 μmol) in dichloromethane (1.0 mL) and
stirred for 2 h at room temperature. The reaction was monitored by
LC MS using gradient 1 as described above, after PFB derivatization
until there was no starting material left. There was only one major
product, which corresponded to 11-oxo-ETE. The reaction mixture was
centrifuged twice at 3,400 rpm (10 min), and the supernatant was
evaporated.Theresiduewasdissolvedinthemobilephase(800μL)and
purifiedbyisocraticmethod2asdescribedabove.Theretentiontimefor
11-oxo-ETEwas13.1min.Highresolutionaccuratemassmeasurements
wereobtainedusingelectrosprayionizationonaThermoLTQ-FTmass
spectrometer ataresolutionof100,000 (datanotshown). NMRspectra
were obtained on a Bruker 500 MHz NMR instrument.
15-PGDH Inhibition in LoVo or HCA-7 Cell Lysates by
CAY10397. LoVo or HCA-7 cells were grown to 90% confluence,
washedwith10mLofphosphate-bufferedsaline(PBS)buffer(2times),
and then gently scraped in 600 μL of lysis buffer containing 0.1 M Tris-
HCl (pH 7.9) and the protease inhibitor. Cell suspension was trans-
ferred to 2mLEppendorftubesandsonicated for60 sonice(power 5).
Figure 2. Chemical structures of COX-2-derived eicosanoids.2230 dx.doi.org/10.1021/tx200336f |Chem. Res. Toxicol. 2011, 24, 2227–2236
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Cell lysate was then incubated with or without the selective 15-PGDH
inhibitor(CAY10397,50μM)anditscofactor(NAD
+,500μM)for10min
at 37 C. The pH was then adjusted to 4 with 10% aqueous acetic acid
(10μL) followed by addition of the internal standard mix, [
13C20]-15-oxo-
ETE, [
2H8]-15(S)-HETE and [
2H4]-PGE2 (50 pg/μL, 20 μL). Diethyl
ether (600 μL )w a sa d d e d ,a n ds a m p l e sw e r ev ortex-mixed and centrifuged
(15000 rpm   2 min). The organic layer was evaporated under nitrogen,
and then the eicosanoids were derivatized with PFB bromide as mentioned
above. Finally, samples were redissolved in hexane/ethanol (95:5; v/v,
100 μL )a n da n a l y z e d( 2 0μL) by normal phase LC-ECAPCI/MS. The
amounts of eicosanoids were normalized by protein concentrations of each
lysate, which were determined by BCA assay.
Metabolism of AA by LoVo or HCA-7 Cells. LoVo or HCA-7
cells were grown to 90% confluence in 6-well plates as described above,
and then fedfreshserum-freeF-12KorDMEM medium. Cells werethen
incubatedwithAA(10μM)for0,5,10,and30min,1and2.5hat37C.
At each time point, 0.6 mL of medium was taken out, and 20 μLo f1 0 %
aqueousaceticacidwasaddedtoadjustpHto3 4,togetherwith20μLof
internalstandardsmixture(50pg/μL[
13C20]-15-oxo-ETE,[
2H8]-15(S)-
HETE, [
2H4]-PGE2 and [
2H4]-13,14-dihydro-15-keto-PGE2-PFB). Then
diethyl ether (1 mL) was added, and the mixture was vortex-mixed and
centrifuged(15000rpm 2min).Theupperetherlayerwasevaporated
under nitrogen, and PFB derivatives were synthesized as described
above and analyzed by normal phase LC-ECAPCI/MS.
Standard Curves for Eicosanoid Quantification. To quantify
eicosanoidsexcretedinthemedium,Eppendorftubescontaining0.6mL
ofF12Kmediumwerespikedwithlipidstandards,togetherwithinternal
standards for [
13C20]-15-oxo-ETE, [
2H8]-15(S)-HETE, [
2H4]-PGE2
and [
2H4]-13,14-dihydro-15-keto-PGE2-PFB (1 ng each). To quantify
eicosanoids in the cell lysate, lipid standards and internal standards
mixture were spiked into 0.2 mL of Tris-HCl buffer. The extraction and
PFB derivatization methods are the same as mentioned above.
Analysis of 11-OEG Adducts in LoVo cell Lysate. LoVo cells
were grown to 90% confluence and then washed with PBS (10 mL).
Cellsweregentlyscrapedin600μLofTris-HClbuffer(0.1M,pH=7.9),
containing protease inhibitor. Cell lysates were transferred to 2 mL
Eppendorf tubes and sonicated for 60 s on ice (power 5). 11-Oxo-ETE
(20 ng in ethanol) was added to the lysate together with 1 mM GSH.
Afterincubationfor25minat37C,10μLof10%aceticacidwasadded,
and the sample was loaded onto an SPE column (Oasis HLB, 30 mg)
preconditioned with methanol and then 0.1% formic acid. The column
waswashedwith1mLofwaterandelutedwith250μLofmethanol,and
then 20μLwasanalyzed byreversed phase LC ESI/MSusinggradient
3, as described above.
Cell Proliferation Assay. BrdU incorporation in HUVECs was
used to assess the effects of 11-oxo-ETE on cell proliferation. The BrdU
assay was performed in a 96-well format using a commercially available
colorimetric enzyme-linked immunosorbent assay (ELISA) kit (Roche),
andalsobyimmunofluorescencemicroscopy.EqualnumbersofHUVECs
in passage 4 were plated on either collagen-I coated 96-well plates (2000
cells/well) or collagen-I coated 8-chamber tissue culture glass slides
(10000 cells/chamber). Cells were allowed to attach overnight in 0.25%
DMSO containing medium. Eicosanoids were dissolved in DMSO, such
thatthefinalconcentrationofDMSOincellmediumwasalways0.25%or
lower.Cellswerethentreatedfor24hwitheithervehicle(0.25%DMSO),
11-oxo-ETE (1 nM to 100 μM), or 15d-PGJ2 (1 nM to 100 μM). After
18 h of treatment, BrdU (final concentration, 10 μM in 0.25% DMSO)
was added to each treatment group for an additional 6 h.
For the colorimetric ELISA, the manufacturer’s protocol was fol-
lowed to perform the assay. The absorbance at λ = 370 nm obtained
from the assay was transformed to the cell numbers using a standard
curve constructed by plating known number of HUVECs in triplicate.
The IC50 values for eicosanoid inhibition of HUVEC proliferation were
deﬁned as the half maximal inhibitory concentration for endothelial cell
proliferation over 24 h when compared with vehicle-treated cells. They
were determined from the regression lines of the log inhibitor vs
response curves using a least-squares ﬁt.
For the immunoﬂuorescence staining, cells were ﬁxed with neutral
buﬀered formalin for 10 min, permeabilized with methanol for 20 min,
and then DNA was denatured by pressure cooking the slides in 10 mM
citric acid buﬀer, pH 6 for 1 h. Cells were then incubated overnight with
rat anti-BrdU antibody (1:1000, Accurate Chemical & Scientiﬁc Corp.)
at 4 C, followed by 30 min incubation at 37 C with Cy3-conjugated
donkeyanti-ratsecondaryantibody(1:600,JacksonImmunoResearch).
Cells were counterstained with 40,6-diamidino-2-phenylindole (DAPI,
Invitrogen) and visualized using a Nikon E600 microscope equipped
with diﬀerential interference contrast (Nomarski) optics and photo-
graphed ( 200 magniﬁcation) with a Fast 1394 QICam (QImaging).
Positive BrdU staining was quantiﬁed by image analysis using IVision
Analysis Software (Biovision). The percentage of proliferating cells was
determined by counting the BrdU-positive cells versus the total number
of cells in randomly selected microscopic ﬁelds (10/replicate) for each
treatment group.
Statistical Analyses. All experiments were conducted in triplicate,
unless otherwise indicated. Statistical significance (p value e0.05) was
determined using a two-tailed unpaired t test employing GraphPad
Prism software (v 5.01).
’RESULTS
Biosynthesis of 11-Oxo-ETE by 15-PGDH. Various concen-
trations of 11(R)-HETE were incubated with recombinant
human 15-PGDH and NAD
+ at 37 C. A Michaelis Menten
kinetic analysis of 11-oxo-ETE formation provided the Vmax
(296 nmol/min/mg of protein), Km (3.42 μM), and kcat
(8.6 min
 1) values for oxidation of 11(R)-HETE (Figure 3) and
theVmax(403.8nmol/min/mgofprotein,Km(1.65μM), and kcat
(8.6min
 1) valuesforoxidationof 15(S)-HETE(Supplementary
Figure 1 in the Supporting Information). Therefore, the catalytic
efficiency (kcat/Km) for 15-PGDH-mediated oxidation of 11(R)-
HETE (2513 min
 1 mM
 1, Figure 3) was 35% of that found for
Figure 3. Kinetic plot of the formation of 11-oxo-ETE by 15-PGDH.
Various concentrations of 11(R)-HETE (0 23 μM) were incubated
with 9 nM recombinant 15-PGDH (52.2 ng, 1.8 pmol) and cofactor
NAD
+. Determinations for 11-oxo-ETE were conducted in triplicate
(means ( SEM) by stable isotope dilution LC ESI/MS analyses.2231 dx.doi.org/10.1021/tx200336f |Chem. Res. Toxicol. 2011, 24, 2227–2236
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15(S)-HETE(7091min
 1mM
 1;SupplementaryFigure1inthe
Supporting Information).
ChemicalSynthesisofAuthentic11-Oxo-ETE.11-Oxo-ETE
was synthesized chemically by oxidizing racemic 11(R,S)-HETE
using the Dess Martin reagent, and then purified using chro-
matographic separation. A combined total of 10 mg of the
racemic 11(R,S)-HETE resulted in the isolation of 4.9 mg of
pure 11-oxo-ETE (overall yield of 49%). High resolution elec-
trospray ionization MS of 11-oxo-ETE revealed accurate masses
of m/z 319.2263 and m/z 341.2079 for the protonated and
sodiated molecules, respectively [calculated accurate mass for
protonated (C20H31O3) and sodiated (C20H30O3Na) mol-
ecules, m/z 319.2273 and m/z 341.2093, respectively]. 500
MHz
1H NMR (δH, CDCl3; Supplementary Figure 2 in the
Supporting Information): 7.55 (dd, J1 = 11.5 Hz, J2 = 15.5, 1H),
6.21(d, J =15.5 Hz, 1H), 6.15 6.11 (m, 1H), 5.97 5.92 (m,
1H), 5.60 5.58 (m, 2H), 5.41 5.38 (m, 2H), 3.35 (d, J = 4.5
Hz, 2H), 2.83 2.81 (m, 2H), 2.38 2.31 (m, 4H), 2.17 2.12
(m,2H),1.74 1.25(m,8H),0.89(t,J=7.0Hz,3H).Analysisof
purified 11-oxo-ETE as its PFB derivative by LC-ECAPCI/MS
(Figure4a) revealedanintensenegativeionatm/z317corresponding
to [M   PFB]
 .C I Do f[ M  PFB]
  (m/z 317) and MS/MS
analysis revealed major product ions at m/z 273, 219, 165, 149, and
123. The UV spectrum was consistent with the presence of a
conjugated dienone with a UV λmax at 279 nm and molecular
extinction coefficient (ε)o f1 8 , 9 8 5M
 1 cm
 1.
Confirmation of 11-Oxo-ETE Identity by LC MS and MS/
MSAnalyses.TheLoVocelllineisknowntoexpressbothCOX-
2 and 15-PGDH and only trace amounts of COX-1;
10,28 this was
confirmed by Western blot analysis (data not shown). Cell
lysates were incubated with 100 nM 11(R)-HETE in the pre-
sence of 500 μM NAD
+ for 10 min. LC MS analysis of PFB
derivatives of eicosanoids extracted from the LoVo cell lysate
Figure 4. Conﬁrmation of 11-oxo-ETE formation by LC MS/MS
analysis. Speciﬁc product ions observed by CID and MS/MS analysis of
[M-PFB]
￿ (m/z 317), corresponding to 11-oxo-ETE are shown on the
relevant chemical structures. (a) Synthetic 11-oxo-ETE-PFB standard;
(b)15-PGDH-derived11-oxo-ETE-PFBfromLoVocelllysatetowhich
100 nM 11(R)-HETE had been added.
Figure 5. Targeted chiral lipidomics analysis of COX-2-derived eico-
sanoids from LoVo cells. LoVo cells were lysed; eicosanoids were
extracted, derivatized with PFB bromide, and analyzed by LC-ECAP-
CI/SRM/MS.LoVocelllysateswerepretreatedwith50μMCAY10397
to inhibit 15-PGDH to be able to detect the 11-, 15-HETEs and PGE2.
Representativechromatogramsareshownfor(toptobottom)(a)11(R)-
HETE-PFB (m/z 319 f 167), (b) [
2H8]-15(S)-HETE-PFB internal
standard (m/z 327 f 226), (c) 11-oxo-ETE-PFB (m/z 317 f 165) and
15-oxo-ETE-PFB (m/z 317 f 165), (d) [
13C20]-15-oxo-ETE-PFB
internal standard (m/z 337 f 120), (e) PGE2-PFB (m/z 351 f 271),
(f)[
2H4]-PGE2-PFB(m/z355f275),(g)13,14-dihydro-15-oxo-PGE2-
PFB (m/z 351 f 235), (h) [
2H4]-13,14-dihydro-15-oxo-PGE2-PFB
(m/z 355 f 239).2232 dx.doi.org/10.1021/tx200336f |Chem. Res. Toxicol. 2011, 24, 2227–2236
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showed that there was a single major metabolite, which eluted at
12.8 min (data not shown). The full scan mass spectrum of this
metabolite had only one major ion at m/z 317 corresponding to
[M   PFB]
  (Figure 4b). CID and MS/MS analysis revealed
theformationofintenseproductionsatm/z123,149,165,219,
and 273 (Figure 4b). The product ion spectrum was identical
with that obtained from authentic synthetic 11-oxo-ETE-PFB
(Figure 4a), which confirmed the identity of 11-oxo-ETE from
LoVo cells. The product ion at m/z 165 in LoVo cell-derived
and synthetic 11-oxo-ETE-PFB corresponded to cleavage be-
tween C-9 and C-10, and m/z 123 was formed from cleavage
between C-11 and C-12 (Figure 4).
Separation of Eicosanoids by Chiral LC-ECAPCI/SRM/MS.
Lysates from LoVo cellswereextractedfor the eicosanoids, which
were then analyzed (after PFB derivatization) by LC-ECAPCI/
SRM/MS. A representative chromatogram (Figure 5) reveals the
separation of 11-oxo-ETE (retention time 12.8 min) and 15-oxo-
ETE (retention time 12.0 min) that were formed in the LoVo cell
lysate. Additional eicosanoids that were observed (Figure 5)
include 13,14-dihydro-15-keto-PGE2 (retention time, 33.6 min),
11(R)-HETE (retention time, 10.0 min), and PGE2 (retention
time, 29.4 min).
Inhibition of 15-PGDH by CAY10397 in LoVo and HCA-7
Cell Lysates. In contrast to LoVo cells, the HCA-7 cell line is
known to express COX-2 and only trace amounts of COX-1 and
15-PGDH.
10,29 This was confirmed by Western blot analysis
(data not shown). LoVo (Figure 6a) or HCA-7 (Figure 6b) cell
lysates were incubated with 500 mM NAD
+, with or without the
15-PGDH inhibitor, CAY10397 (50 μM), for 10 min. Inhibition
of 15-PGDH significantly abolished the formation of endogen-
ous 11-oxo-ETE (Figure 6a) by 92%, along with the diminished
formation of 15-oxo-ETE as well as 13,14-dihydro-15-oxo-PGE2
(Figure6a)intheLoVocelllysate.However,sincetheoxo-ETEs
and13,14-dihydro-15-oxo-PGE2wereundetectableinHCA-7cell
lysate, their precursors were quantified instead, and CAY10397
had no effect on their levels (Figure 6b).
Secretion of Eicosanoids from LoVo and HCA-7 Cells
Following AA Addition. Time-course analyses for the amount
of different eicosanoids secreted by LoVo and HCA-7 cells
following AA incubation for 0 2.5 h are shown in Figure 7a
and Figure 7b, respectively. 11-Oxo-ETE was secreted into the
cell medium by LoVo cells along with 15-oxo-ETE and 13,14-
dihydro-15-oxo-PGE2 (Figure 7a). Interestingly, both 11-oxo-
ETE and 15-oxo-ETE reached maximum concentrations 10 min
after the addition of AA to the cells. This was followed by a
decline of both eicosanoids to steady-state levels after 2.5 h
(Figure7a)inLoVocells.Incontrast,13,14-dihydro-15-oxo-PGE2
Figure 6. Inhibition of 15-PGDH in LoVo and HCA-7 cell lysates by
CAY10397.(a)LoVoor(b)HCA-7celllysate(1 10
6cells/treatment
group) was incubated with or without CAY10397 (50 μM to inhibit 15-
PGDH). Eicosanoids were extracted from the lysates, and their levels
were determined by chiral LC-ECAPCI/SRM/MS. Analyses were
performed in triplicate, and error bars show SEM.
Figure 7. Time course for eicosanoids secreted from LoVo and HCA-7
cells following AA incubation. (a) LoVo or (b) HCA-7 cells were
incubated with 10 μM AA for 0 6 h.The diﬀerenteicosanoids secreted
into the medium at various time points were extracted, and their levels
were determined by stable isotope dilution LC-ECAPCI/SRM/MS
analysis of their PFB derivatives. Determinations were conducted in
triplicate(means(SEM),andthequantitationwasperformedusingthe
standard curves generated for these eicosanoids.2233 dx.doi.org/10.1021/tx200336f |Chem. Res. Toxicol. 2011, 24, 2227–2236
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levels did not peak until 1 h after the addition of AA (Figure 7a)
and remained constant throughout the remainder of the incuba-
tionperiod.However,levelsoftheeicosanoids(11-oxo-ETE,15-
oxo-ETE or 13,14-dihydro-15-oxo-PGE2) resulting from 15-
PGDH-mediated metabolism were below detection limits in
the medium of HCA-7 cells incubated with AA and, hence, are
not displayed in Figure 7b. PGE2 was secreted in the medium
from HCA-7 cells incubated with AA (Figure 7b) demonstrating
that the COX-2-mediated AA metabolism occurred. This ruled
out the possibility that an artifact was responsible for lack of
detectionof 11-oxo-ETE, 15-oxo-ETEor 13,14-dihydro-15-oxo-
PGE2 in the HCA-7 cell media.
Formation of 11-OEG in LoVo Cell Lysates. Biosynthesis
of 11-OEG was monitored in the cell lysate after the addition of
100 nM11-oxo-ETE and1mMGSH totheLoVo celllysate. 11-
OEG formation was detected and confirmed by LC MS/MS
monitoring of the major metabolite formed after a 30 min
incubation. OEG (retention time, 32.2 min, data not shown)
was observed as an intense peak in the LC ESI/MS chromato-
gramwhenanalyzedbygradient3(asdescribedabove).CIDand
MS/MS analysis revealed the formation of intense product ions
at m/z 497, 319, 308, and 179 (Figure 8).
Effects of Eicosanoids on HUVEC Proliferation. Prolifera-
tion by HUVECs was assessed by quantifying the BrdU incor-
porationintothecellsactivelysynthesizingnewDNA.TheBrdU
assay was performed using a quantitative colorimetric 96-well
format ELISA as well as by immunofluorescence microscopy for
observing the morphological effects of eicosanoids in HUVECs.
For the BrdU ELISA, HUVECs (2000 cells/well) were treated
with different doses (0 100 μM) of 11-oxo-ETE and 15d-PGJ2
for a period of 24 h. The cell numbers corresponding to each
treatment dose were computed and used to calculate cell
proliferation (%) as compared to the vehicle-treated controls.
11-Oxo-ETE (IC50 = 2.1 μM) was equipotent with 15d-PGJ2
(IC50 = 2.3 μM), a known potent inhibitor of endothelial cell
proliferation (Figure 9a). For the immunofluorescence analysis,
HUVECs (8000 cells/chamber) were treated with either 2 μM
11-oxo-ETEor2μM15d-PGJ2for24h.BrdUincorporationwas
assessed by counting the BrdU-positive cells as compared to the
total number of cells counted in randomly selected microscopic
fields(10fields/treatment).Thephotomicrographsclearlyshow
that treatment with 11-oxo-ETE as well as 15d-PGJ2 remarkably
reduced the total number of BrdU-positive cells (stained red) as
compared to vehicle-treated controls (Figure 9b). Moreover,
there was a distinct change in the morphological appearance of
the DAPI-stained (stained blue) cells in the eicosanoid-treated
slides that failed to incorporate BrdU (Figure 9b).
’DISCUSSION
15-PGDHcatalyzesNAD
+-mediatedoxidation of the15(S)-
hydroxyl moiety of PGs and other eicosanoids (Figure 1).
10,16,26
Our previous studies had established that 15-PGDH is also
responsible for metabolizing the 15-lipoxygenase-derived 15(S)-
HETE in macrophages and monocytes to 15-oxo-ETE.
26 Surpris-
ingly,wehavenowfoundthat11(R)-HETEisalsometabolizedby
Figure 8. LC MS/MS analysis of 11-OEG adduct. 11-OEG was
synthesized by reacting 200 nM 11-oxo-ETE and 1 mM GSH in LoVo
celllysatefor25minat37C.Theproduct wasextracted bysolid-phase
extraction and analyzed by LC ESI/MS/MS. Speciﬁc product ions
observed by CID of [MH]
+ (m/z 626) are shown with their relevant
chemical structures in the MS/MS analysis of 11-OEG.
Figure9. EﬀectofeicosanoidsoncellproliferationofHUVECs.(a)For
BrdU ELISA, HUVECs (2000 cells/well) were treated with various
doses of 11-oxo-ETE and 15d-PGJ2 for a period of 24 h. Cell prolifera-
tion (means ( SEM) was assessed by measuring absorbance at 370 nm
andconvertingittocellnumbersusingastandardcurveandtherebyused
toconstructtheIC50plots.Allexperimentswereconductedthreetimesin
triplicate.Representativedatafromoneexperimentconductedintriplicate
are shown as means ( SEM. (b) For immunoﬂuorescence, HUVECs
(8000/chamber)weretreatedwith2μM15 d- PG J 2or2μM11-oxo-ETE
for 24 h and then stained for BrdU and counterstained with DAPI (cells
stained blue). Photomicrographs were taken at  200 magniﬁcation, and
BrdU-positive (stained purple) cells were counted in randomly selected
microscopicﬁelds(10/replicate)ascomparedtothetotalnumberofcells
in these ﬁelds. All experiments were conducted in triplicate. Representa-
tive photomicrographs from one set of replicates are shown.2234 dx.doi.org/10.1021/tx200336f |Chem. Res. Toxicol. 2011, 24, 2227–2236
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15-PGDH to a novel eicosanoid, that was identiﬁed as 11-oxo-
ETE (Figure 2). The catalytic activity of human 15-PGDH for
oxidationof11(R)-HETE(Figure2)wasapproximatelyone-third
of that observedfor 15(S)-HETE (Supplementary Figure1 in the
Supporting Information). These results were very surprising in
viewofthelackofa15(S)-hydroxylgroupon11(R)-HETEaswell
as the incorrect 11(R)-stereochemistry. The structure of 11-oxo-
ETE metabolite was established by chemically synthesizing
authentic 11-oxo-ETE from racemic 11-HETE. 11-Oxo-ETE
was formed in LoVo cell lysates (Figure 6a) and secreted from
intact cells (Figure 7a); whereas 11-oxo-ETE was not formed by
HCA-7 cell lysates (Figure 6b) or secreted from intact cells
(Figure7b).SinceLoVocellsexpressCOX-2aswellas15-PGDH,
whereas HCA-7 cells express COX-2 but not 15-PGDH,
10,28,29
these data convincingly prove that 11-oxo-ETE is an endogenous
product formed enzymatically by a combination of COX-2 and
15-PGDH.
11-Oxo-ETEisisomericwith15-oxo-ETE(Figure 2) andalso
has very similar LC properties. Therefore, a reversed phase LC-
SRM/MS method was developed to separate the underivatized
oxo-ETEs, and normal phase was implemented to separate their
PFB derivatives. This made it possible to readily analyze the two
oxo-ETEs. Endogenous eicosanoids formed by LoVo and HCA-
7 epithelial cells and cell lysates as well as those formed after the
addition of AA were analyzed as PFB derivatives by chiral LC-
ECAPCI/MS.
30,31 Representative chromatograms of the eicosa-
noidsproducedendogenouslyintheLoVo celllysatesareshown
in Figure 5. Inhibition of 15-PGDH enzyme by CAY10397 sig-
niﬁcantly diminished the formation of endogenous 11-oxo-ETE
in LoVo cell lysates (Figure 6a). In addition, the formation of
15-oxo-ETEaswell as13,14-dihydro-15-oxo-PGE2, theothertwo
15-PGDH-dependent metabolites, was also signiﬁcantly reduced
in LoVo cell lysates treated with CAY10397 (Figure 6a). In
contrast, the three 15-PGDH products, namely, 11- and 15-
oxo-ETE and 13,14-dihydro-15-oxo-PGE2, were undetectable in
HCA-7 cells as these cells do not express any 15-PGDH.
10,28
Instead,thecorrespondingprecursorsforthesethreemetabolites
were observed in the lysates. Furthermore, treatment with
CAY10397hadnoeﬀectonlevelsof11(R)-HETE,15(S)-HETE
orPGE2(Figure6b).IntactLoVocellsalsosecreted11-oxo-ETE
and 15-oxo-ETE as well as 13,14-dihydro-15-oxo-PGE2. How-
ever, the 11-oxo-ETE was cleared very rapidly (Figure 7a),
suggesting that further metabolism was occurring. Subsequently,
itwasobservedthat11-oxo-ETEunderwentGSHconjugationto
form 11-OEG, similar to the formation of 15-OEG in RIES cells
(Figure 8).
1 GSH conjugation was predominantly catalyzed by
the GST enzymes; however, it can also occur in a nonenzymatic
manner. The relative amount of 11-OEG formed from these
diﬀerent pathways was not explored in detail in the present
studies.
We realized that, despite its being a linear molecule, 11-oxo-
ETE has structural similarities to the cyclopentenone eicosanoid
15d-PGJ2 due to the presence of an 11-oxo moiety and a Δ
12,14-
diene (Figure 2). This suggested that 11-oxo-ETE might be a
more eﬀective inhibitor of HUVEC proliferation than 15-oxo-
ETE
26withapotencysimilar tothat observed for15d-PGJ2.
19In
fact, 11-oxo-ETE was six times more potent than 15-oxo-ETE
(data not shown) and equipotent with 15d-PGJ2 at inhibition of
HUVEC proliferation (Figure 9). Dose response studies revealed
that its IC50 was 2.1 μMc o m p a r e dt oa nI C 50 value of 2.3 μMf o r
15d-PGJ2(Figure9a). Moreover, immunoﬂuorescence microscopy
revealed that 11-oxo-ETE not only inhibited BrdU incorporation
into the HUVECs but also caused a dramatic change in the shape
and morphology of these cells (Figure 9b). Although the total
number of cells counted in the eicosanoid-treated groups was quite
similar to that in the vehicle-treated group, the BrdU-negative cells
were signiﬁcantly distorted (Figure 9b). Typically, if the cells are
undergoing death by apoptosis, they would appear more com-
pact and round. However, 11-oxo-treated cells were elongated
andstretched(Figure9b), whichcouldbeindicativeofextensive
cytoskeletal remodeling, cell cycle arrest and/or diﬀerentiation.
Interestingly, 11-oxo-ETE formation could not be detected in
HUVEC lysate that was incubated with 11(R)-HETE (data not
shown). Furthermore, immunoblot analysis of HUVEC cell
lysate failed to detect COX-2 protein (data not shown). Taken
together, these data suggest a paracrine role for 11-oxo-ETE on
endothelial cell proliferation.
Asnoted above, inhibition of 15-PGDH resultedin signiﬁcant
decreases in11-oxo-ETEformation inLoVo cells (Figure 6).15-
PGDHisdownregulatedinnumerouscancertypes,
7,10 14which
would cause a decrease in 11-oxo-ETE biosynthesis by pre-
venting the in vivo conversion of 11(R)-HETE to 11-oxo-ETE
(Figure 1). This could be particularly devastating as COX-2
becomes upregulated during tumorigenesis, which would result
in elevated PGE2 biosynthesis along with decreased 15-PGDH-
mediatedinactivation to 15-oxo-PGE2 (Figure1). Ultimately,this
would result in an increase in PGE2-mediated proproliferative
activity
6,15 without the counter eﬀect of antiproliferative oxo-
ETEs. IncreasedPGE2 activitycanalso arisethroughdownregula-
tion of the inﬂux PG transporter: the organic anion transporter
polypeptide (OATP) 2A1 (Figure 1).
32,33 PGE2 and 11-oxo-ETE
can also arise from the metabolism of AA by constitutively
expressedCOX-1.Therefore,downregulationof15-PGDHwould
also prevent the inactivation of COX-1-derived proproliferative
PGE2 as well as the biosynthesis of antiproliferative 11-oxo-ETE.
These metabolic changes could also contribute to the eicosanoid-
mediated eﬀects that occur during tumorigenesis.
There is some evidence that 11-oxo-ETE can activate nuclear
PPARγ.
34 PPARγ is a ligand-dependent transcription factor
responsible for the regulation of a number of cellular events
ranging from lipid metabolism to apoptosis.
35 15d-PGJ2 is a
PPARγ agonist, which might account for its ability to inhibit
endothelial cell proliferation.
18,19 However, this eﬀect is only
observed with pharmacological amounts of 15d-PGJ2 rather
than endogenous concentrations.
27 Besides PPARγ agonistic
activity, 15d-PGJ2 is also known to be an inhibitor of NFkB
signaling,apathwaycriticaltocellproliferationaswellastumo-
rigenesis.
36,37 In view of the ability of COX-2/15-PGDH to
rapidly metabolize AA to nM amounts of oxo-ETEs, together
with the similar structural features of the oxo-ETEs and 15d-PGJ2
(Figure 2), it will be important to determine which of these
activitiesaresharedbybothclassesofeicosanoids.Itisnoteworthy
that docosahexaenoic acid and docosapentaenoic acid can be
metabolized by the sequential action of COX-2 and dehydro-
genases into oxoeicosanoids that modulate the antioxidant
response.
38 Similarly 5-lipoxygenase-derived 5(S)-HETE is meta-
bolized by5-hydroxyeicosanoiddehydrogenaseintothechemoat-
tractant 5-oxo-ETE.
39 Therefore, the oxoeicosanoids represent a
family of oxidized lipids with diverse biological activities.
In summary, our studies have revealed that inhibition of 15-
PGDH prevents the formation of endogenous antiproliferative
eicosanoid, 11-oxo-ETE. Therefore, 15-PGDH has two quite
distinctproperties:itcaneitherinactivatePGsoractivateHETEs
to oxo-ETEs that exert a paracrine eﬀect on endothelial cells2235 dx.doi.org/10.1021/tx200336f |Chem. Res. Toxicol. 2011, 24, 2227–2236
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(Figure 1). 11-Oxo-ETE, a member of the oxo-ETE family,
39 41
wasobserved previouslyasan endogenouslyderived lipid in human
atheroscleroticplaques.
42However,thebiosynthesisof11-oxo-ETE
and its biological activity were not evaluated in that study. Further-
more, there does not appear to be any subsequent report of its
formation either in vitro or in vivo. We have now shown that in fact
11-oxo-ETE is derived from COX-2/15-PGDH-mediated AA
metabolism and that it inhibits endothelial cell proliferation with
an IC50 that is very similar to that of 15d-PGJ2.
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11-HETE, 11-hydroxy-5,8,12,14-(Z,Z,E,Z)-eicosatetraenoic acid;11-
oxo-ETE,11-oxo-5,8,12,14-(Z,Z,E,Z)-eicosatetraenoicacid;15-HETE,
15-hydroxy-5,8,11,13-(Z,Z,Z,E)-eicosatetraenoic acid;15-oxo-ETE,
15-oxo-5,8,11,13-(Z,Z,Z,E)-eicosatetraenoic acid;15d-PGJ2, 15-
deoxy-Δ
12,14-prostaglandin J2;15-PGDH, 15-hydroxyprosta-
glandin dehydrogenase;AA, arachidonic acid;ABC, ATP binding
cassette;BrdU, 5-bromo-2-deoxyuridine;CAY10397, 5-[[4-(ethoxy-
carbonyl)phenyl]azo]-2-hydroxy-benzeneaceticacid;COX,cy-
clooxygenase;CID, collision-induced dissociation;cPLA2, cyto-
solic phospholipase A2;Dess Martin reagent, [1,1,1-tris(acetyloxy)-1,
1-dihydro-1,2-benziodoxol-3-(1H)-one];ECAPCI, electron
capture atmospheric pressure chemical ionization;ELISA, en-
zyme-linked immunosorbent assay;ESI, electrospray ionization;
GSH, glutathione;GST, glutathione S-transferase;HPETE, hy-
droperoxyeicosatetraenoic acid;HUVEC, human umbilical vein
endothelial cells;IC50, half-maximal inhibitory concentration;LC,
liquid chromatography;LSGS, low-serum growth supplement;
MS, mass spectrometry;NSAID, nonsteroidal anti-inﬂammatory
drug;OATP, organic anion transporter polypeptide;OEG, oxo-
ETE-GSH adduct;PBS, phosphate-buﬀered saline;PG, prostaglan-
dinPOX, peroxidase;PPAR, peroxisome proliferator-activated
receptor;PFB, 2,3,4,5,6-pentaﬂuorobenzyl bromide;RIES cells,
rat intestinal epithelial cells stably expressing COX-2;SRM,
selected reaction monitoring.
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